Pain | Jotup

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

Branches of biology, Nervous system, Symptoms and signs, Pain, Nociception, Acute pain, Suffering, Drug rehabilitation, Ibogaine, Neuropathic pain, Psychological trauma

Thursday, March 4, 2021 - 8:30am

Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.

Key Points:

Recently, the Company's PsyCollage platform has identified the opportunity for the use of ibogaine to address neuropathic pain and brain trauma.
"PsyCollage ensures we are moving in the right direction in our mission to provide alternative and effective treatment options for psychological and physiological pain," said Kelsey Ramsden, President & CEO, MINDCURE.
"Ibogaine has centuries of therapeutic history reinforcing its potential to heal pain.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health.

Global Healthtech Innovator NuroKor Accelerates US Expansion With Major New 5 Year Medi-Launch Partners Partnership and International Investment

Wednesday, March 3, 2021 - 12:43pm

Leading bioelectronic innovator NuroKor BioElectronics has announced plans to ramp up its US expansion, following 12 months of rapid growth during which the companys half-year sales rose by 156%.

Key Points:

Leading bioelectronic innovator NuroKor BioElectronics has announced plans to ramp up its US expansion, following 12 months of rapid growth during which the companys half-year sales rose by 156%.
Our partnership with Medi-Launch Partners will be instrumental in ensuring we are able to distribute as far and wide as possible, reaching those who need highly effective, non-invasive pain relief.
As the only life sciences company of its kind worldwide, NuroKor is playing an important role in changing the way medical professionals and patients approach pain management.
The latest clinical investor to join the NuroKor team is Dr Alaina Edgemon, head of the Florida Natural Medicine & Pain Centre.

Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)

Branches of biology, Neuroscience, Neurotechnology, Neurological disorders, Neuromodulation, Neurophysiology, Neuropsychology, Pain, Obstructive sleep apnea

Wednesday, March 3, 2021 - 5:58am

Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population.

Key Points:

Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population.
For now, these patients are contra-indicated for existing Hypoglossal Nerve Stimulation OSA therapies.
Nyxoah is currently conducting the BETTER SLEEP study, that aims to assess the effectiveness of the Genio system bilateral hypoglossal nerve stimulation for Complete Concentric Collapse (CCC) patients and to build clinical evidence for a potential therapeutic indication expansion.
We will be announcing the full results of our BETTER SLEEP study in May 2021.

CCHP Partners with Kiio to Support Medicaid and Marketplace Members During COVID-19 with an Evidence-Based Pain Management Solution

Nervous system, Branches of biology, Symptoms and signs, Child poverty, Federal assistance in the United States, Healthcare reform in the United States, Medicaid, Presidency of Lyndon B. Johnson, KIIO-LD, Pain, CCHP, Marketplace

Tuesday, March 2, 2021 - 5:35pm

CCHP initially rolled Kiio out to its Medicaid and Marketplace members in early 2019 and saw very strong results for Kiio participants in the first year.

Key Points:

CCHP initially rolled Kiio out to its Medicaid and Marketplace members in early 2019 and saw very strong results for Kiio participants in the first year.
Members using Kiio experienced a 61% reduction in pain and a 52% improvement in function on average.
Also, 90% of members said Kiio helped them learn to better manage their pain.
We are proud to serve over 160,000 members between our two products, Medicaid and Together with CCHP Marketplace product.

New survey finds stress-related dental conditions continue to increase

Musculoskeletal disorders, Temporomandibular joint dysfunction, Dentist, Health, Pain, Dentistry

Tuesday, March 2, 2021 - 3:50pm

This is an increase from ADA data released in the fall that showed just under 60 percent of dentists had seen an increase among their patients.

Key Points:

This is an increase from ADA data released in the fall that showed just under 60 percent of dentists had seen an increase among their patients.
The increase over time suggests stress-related conditions have become substantially more prevalent since the onset of COVID-19.
The survey also found a little more than 60 percent of dentists saw an increase in other stress-related dental conditions including chipped and cracked teeth and TMD (temporomandibular joint disorder) symptoms such as headaches and jaw pain.
As the pandemic continues, dentists are seeing stress-related dental conditions more and more, said Marcelo Araujo, D.D.S., M.S., Ph.D., ADA chief science officer.

SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA

Branches of biology, Pain, Nervous system, Nociception, Human back, Sensory systems, Low back pain, Chronic pain, Multifidus muscle, Back pain, Transcutaneous electrical nerve stimulation

Tuesday, March 2, 2021 - 3:45pm

In contrast, PNS of the medial branch nerve results in activation of the multifidus muscles, a key postural muscle in the spine.

Key Points:

In contrast, PNS of the medial branch nerve results in activation of the multifidus muscles, a key postural muscle in the spine.
With use of the SPRINT PNS System, a majority of participants in the study saw clinically significant reductions in pain intensity following a 60-day treatment period, with commensurate improvements in functional outcomes.
The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and iscleared for use up to 60 days.
Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.

Womanizer's clinical study shows masturbation helps against period pain

Human behavior, Branches of biology, Nervous system, Sexual acts, Female masturbation, Habits, Male masturbation, Masturbation, Pain, Religious views on masturbation

Tuesday, March 2, 2021 - 8:15am

In May 2020, Womanizer launched the Menstrubation Study (Menstruation + Masturbation) the first clinical study worldwide to find out whether masturbation can help against period pain.

Key Points:

In May 2020, Womanizer launched the Menstrubation Study (Menstruation + Masturbation) the first clinical study worldwide to find out whether masturbation can help against period pain.
The result: Yes, masturbation helps against period pain.
When asked whether masturbation or medication worked better for period pain, equal numbers favoured each method: 43 per cent chose medication, 42 per cent masturbation.
90 per cent would recommend masturbation for pain relief and 85 per cent plan to maintain their (new) masturbation routine after the study.

Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021

Nervous system, Branches of biology, Symptoms and signs, Communication, Forward-looking statement, Pain

Monday, March 1, 2021 - 9:01pm

A replay of the webcast will also be available following the live presentation on the investor section of the Company's website.

Key Points:

A replay of the webcast will also be available following the live presentation on the investor section of the Company's website.
The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation.
These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio.
Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

Natural Personal Care Leader, J.R. Watkins, Launches Disruptive Topical Pain Relief Remedies Nationwide

Branches of biology, Pain, Nervous system, Human back, Analgesics, Nociception, Menthol, Monoterpenes, Back pain, Peppermint

Wednesday, February 24, 2021 - 2:00pm

The MUSCLE and COOLING Pain Relief lines provide ingredient-conscious consumers with better-for-you pain relief alternatives without compromising efficacy.

Key Points:

The MUSCLE and COOLING Pain Relief lines provide ingredient-conscious consumers with better-for-you pain relief alternatives without compromising efficacy.
J.R. Watkins MUSCLE Pain Relief line offers penetrating pain relief for muscle strains and soreness and aching joints - made with natural Camphor and added Magnesium, Vitamin D, and Peppermint.
The COOLING Pain Relief line provides fast-acting pain relief for backaches and joints - made with natural Menthol and added Arnica and Vitamin E. Meet the products:
The MUSCLE Pain Relief Line-Up:
MUSCLE Pain Relief Roll-On is small enough for travel and on-the-go, perfect for targeting muscle strains at home or on-the-go ($16.99)
The COOLING Pain Relief Line-Up:
COOLING Menthol Extra Strength Pain Relief Roll-On is small enough for travel and on-the-go, perfect for targeting joint pain at home or on-the-go ($15.99)
The COOLING line launched on JRWatkins.com, January 26, 2021, and today, MUSCLE is now available on the brand website.
The MUSCLE Pain Relief line will expand into doors nationwide with CVS Pharmacy starting March 5, 2021.

AppliedVR Completes Pivotal Trial Finding Virtual Reality Is a Holistic Treatment for Chronic Pain

Wednesday, February 24, 2021 - 1:00pm

AppliedVR , a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home.

Key Points:

AppliedVR , a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home.
EaseVRx is an eight-week program delivered via a virtual reality medical device which teaches participants how to recognize and adjust cognitive, emotional, and physical responses to chronic pain using one session per day.
Already the most evidence-backed VR provider in healthcare, AppliedVR is engaged with multiple big-name insurers to evaluate its platform as a covered treatment for chronic pain.
AppliedVR is a leader in digital therapeutics, pioneering virtual reality-based treatments that address the complexity of chronic pain.